The FDA recently requested that human research looking at the effect of CBD on liver function be conducted. In response, 12 CBD companies funded a research study looking at CBD and liver health over a 7-month period. Previously, in 2019, findings from a mouse study suggested that extremely high levels of CBD might cause liver injury, raising concerns at the FDA but also questions because it is known that mice and humans deal with CBD in the body differently. This means that findings from rodent studies may not translate to the same effects in humans. Also, humans typically consume much lower doses than were used in the mouse study.
Who Was It?
This study was conducted by Validcare, an independent company that conducts clinical trials. The study recruited 839 healthy adults between August 2020 and February 2021.
What Was Done?
Subjects consumed oral formulations of hemp derived CBD for a minimum of 60 days. Biomarkers of liver function were measured at the end of the study. Subjects were provided CBD at no cost by the sponsoring companies.
There was no clinical evidence of liver disease in any participants, although there were slight non-clinical elevations in liver enzymes in a small percentage of consumers. Also, CBD intake did not increase adverse events in the vast majority of participants with medical conditions who were taking medications. These findings are preliminary and will be published in a peer reviewed scientific journal at a later date.
CBD intake at levels typically consumed by humans appears to have no clinically significant adverse effects on liver health when taken over a two-month period. The study used different doses and formulations of CBD, similar to Fringe Mana (CBD isolate) and Henko (CBD Broad Spectrum), suggesting that Fringe CBD can be safely recommended to patients for a range of health care concerns.